Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients - Czech center experience

被引：5

作者：

Weinbergerova, Barbora ^{[1
,2
]}

Cernan, Martin ^{[3
,4
]}

Kabut, Tomas ^{[1
,2
]}

Semerad, Lukas ^{[1
,2
]}

Podstavkova, Natalia ^{[1
,2
]}

Szotkowski, Tomas ^{[3
,4
]}

Jeziskova, Ivana

Mayer, Jiri ^{[1
,2
]}

机构：

[1] Masaryk Univ, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[2] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[3] Palacky Univ Olomouc, Fac Med & Dent, Dept Hemato Oncol, Olomouc, Czech Republic

[4] Univ Hosp Olomouc, Olomouc, Czech Republic

来源：

HAEMATOLOGICA | 2023年 / 108卷 / 10期

关键词：

CHEMOTHERAPY;

D O I：

10.3324/haematol.2022.282263

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2826 / 2829

页数：4

共 50 条

[31] Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study
Bertoli, Sarah
Dumas, Pierre-Yves
Berard, Emilie
Largeaud, Laetitia
Bidet, Audrey
Delabesse, Eric
Tavitian, Suzanne
Gadaud, Noemie
Leguay, Thibaut
Leroy, Harmony
Rieu, Jean-Baptiste
Vial, Jean-Philippe
Vergez, Francois
Lechevalier, Nicolas
Luquet, Isabelle
Klein, Emilie
Sarry, Audrey
De Grande, Anne-Charlotte
Recher, Christian
Pigneux, Arnaud
CANCERS, 2020, 12 (04)
[32] Concurrent versus sequential or no triazole anti-fungal therapy in patients undergoing 7+3 plus midostaurin induction for FLT-3 acute myelogenous leukemia
Ngo, Dat
Tinajero, Jose
Zhang, Jianying
Stein, Anthony
Marcucci, Guido
Salhotra, Amandeep
Pullarkat, Vinod
Sandhu, Karamjeet S.
Ball, Brian J.
Pourhassan, Hoda
Koller, Paul
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024,
[33] Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
Maziarz, Richard T.
Levis, Mark
Patnaik, Mrinal M.
Scott, Bart L.
Mohan, Sanjay R.
Deol, Abhinav
Rowley, Scott D.
Kim, Dennis D. H.
Hernandez, Daniela
Rajkhowa, Trivikram
Haines, Kelly
Bonifacio, Gaetano
Rine, Patrice
Purkayastha, Das
Fernandez, Hugo F.
BONE MARROW TRANSPLANTATION, 2021, 56 (05) : 1180 - 1189
[34] Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort
Onate, Guadalupe
Pratcorona, Marta
Garrido, Ana
Artigas-Baleri, Alicia
Bataller, Alex
Tormo, Mar
Arnan, Montserrat
Vives, Susana
Coll, Rosa
Salamero, Olga
Vall-Llovera, Ferran
Sampol, Antonia
Garcia, Antoni
Cervera, Marta
Avila, Sara Garcia
Bargay, Joan
Ortin, Xavier F.
Nomdedeu, Josep
Esteve, Jordi
Sierra, Jorge
BLOOD CANCER JOURNAL, 2023, 13 (01)
[35] No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group
Castano-Bonilla, Tamara
Barragan, Eva
Sargas, Claudia
Sanz, Alejandro
Algarra, Lorenzo
Herrera-Puente, Pilar
Garcia-Boyero, Raimundo
Barrios, Manuel
Martinez-Cuadron, David
Rodriguez-Veiga, Rebeca
Boluda, Blanca
Gil, Cristina
Serrano-Lopez, Josefina
Martinez-Lopez, Joaquin
Jose Sayas-Lloris, Maria
Teresa Olave, Maria
Riaza-Grau, Rosalia
Bernal-Del Castillo, Teresa
Jose Larrayoz, Maria
Amigo, Raquel
Jimenez-Velasco, Antonio
Sanchez, Joaquin
Ayala, Rosa
Blas, Carlos
Lainez, Daniel
Serrano-Lopez, Juana
Sanz, Miguel A.
Alonso-Dominguez, Juan M.
Montesinos, Pau
DISEASE MARKERS, 2022, 2022
[36] Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience
Urbino, Irene
Secreto, Carolina
Apolito, Vincenzo
Olivi, Matteo
Arrigo, Giulia
Boscaro, Eleonora
Catania, Federica Maria
D'Ardia, Stefano
Frairia, Chiara
Giai, Valentina
Freilone, Roberto
Bruno, Benedetto
Lanzarone, Giuseppe
Giaccone, Luisa
Busca, Alessandro
Dellacasa, Chiara Maria
Ferrero, Dario
Audisio, Ernesta
Cerrano, Marco
LEUKEMIA RESEARCH, 2024, 136
[37] Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups
Amadori, S
Suciu, S
Willemze, R
Mandelli, F
Selleslag, D
Stauder, R
Denzlinger, C
Leone, G
Fabris, P
Muus, P
Vignetti, M
Hagemeijer, A
Beeldens, F
Anak, O
De Witte, T
HAEMATOLOGICA, 2004, 89 (08) : 950 - 956
[38] Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis
Shimony, Shai
Canaani, Jonathan
Kugler, Eitan
Nachmias, Boaz
Ram, Ron
Frisch, Avraham
Ganzel, Chezi
Vainstein, Vladimir
Moshe, Yakir
Aumann, Shlomzion
Yeshurun, Moshe
Ofran, Yishai
Raanani, Pia
Wolach, Ofir
ANNALS OF HEMATOLOGY, 2022, 101 (09) : 2001 - 2010
[39] Limited efficacy of 3+7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients
Serio, Bianca
Grimaldi, Francesco
Ammirati, Lucia
Annunziata, Mario
De Santis, Giovanna
Perrotta, Alessandra
De Novellis, Danilo
Giudice, Valentina
Morini, Denise
Storti, Gabriella
Califano, Catello
Risitano, Antonio Maria
Pane, Fabrizio
Selleri, Carmine
CANCER REPORTS, 2024, 7 (04)
[40] Combination therapy with azacitidine, etoposide, and cytarabine in the treatment of elderly acute myeloid leukemia patients: A single center experience
Onec, Birgul
Okutan, Harika
Albayrak, Murat
Can, Esra Saribacak
Aslan, Vedat
Koluman, Basak Unver
Kosemehmetoglu, Ozge Soyer
Albayrak, Aynur
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (05) : 1105 - 1111

← 1 2 3 4 5 →